Marker Therapeutics, Inc. is a clinical-stage immuno-oncology company specializing in the development of innovative peptide and nucleic acid-based immunotherapeutic vaccines for the treatment and eradication of cancer, including metastatic cancer. The company's product pipeline consists of MultiTAA T Cell Therapy, TPIV200 and TPIV100/110 which are in clinical stage. Marker Therapeutics Inc., formerly known as TapImmune Inc., is based in FL, United States.
| Revenue (Most Recent Fiscal Year) | $6.59M |
| Net Income (Most Recent Fiscal Year) | $-10.73M |
| PE Ratio (Current Year Earnings Estimate) | -- |
| PE Ratio (Trailing 12 Months) | -- |
| PEG Ratio (Long Term Growth Estimate) | -- |
| Price to Sales Ratio (Trailing 12 Months) | 1.99 |
| Price to Book Ratio (Most Recent Quarterly Book Value per Share) | 0.67 |
| Price to Cash Ratio (Most Recent Annual Cash Flow per Share) | -- |
| Pre-Tax Margin (Trailing 12 Months) | -162.05% |
| Net Margin (Trailing 12 Months) | -162.83% |
| Return on Equity (Trailing 12 Months) | -90.38% |
| Return on Assets (Trailing 12 Months) | -73.13% |
| Current Ratio (Most Recent Fiscal Quarter) | 6.36 |
| Quick Ratio (Most Recent Fiscal Quarter) | 6.36 |
| Debt to Common Equity (Most Recent Fiscal Quarter) | 0.00 |
| Inventory Turnover (Trailing 12 Months) | -- |
| Book Value per Share (Most Recent Fiscal Quarter) | $1.73 |
| Earnings per Share (Most Recent Fiscal Quarter) | $-0.42 |
| Earnings per Share (Most Recent Fiscal Year) | $-1.19 |
| Diluted Earnings per Share (Trailing 12 Months) | $-1.20 |
| Exchange | NASDAQ |
| Sector | Healthcare |
| Industry | Biotechnology |
| Common Shares Outstanding | 11.31M |
| Free Float | 9.67M |
| Market Capitalization | $13.12M |
| Average Volume (Last 20 Days) | 0.04M |
| Beta (Past 60 Months) | 1.29 |
| Percentage Held By Insiders (Latest Annual Proxy Report) | 14.50% |
| Percentage Held By Institutions (Latest 13F Reports) | 22.39% |
| Annual Dividend (Based on Last Quarter) | $0.00 |
| Dividend Yield (Based on Last Quarter) | 0.00% |